Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse large B-cell lymphoma: is morphologic subdivision useful in clinical management?

A Salar1, A Fernández de Sevilla, V Romagosa

  • 1Department of Clincal Haematology, Institut Català d'Oncologia and Hospital Príncipes de España (Ciudad Sanitaria y Universitaria de Bellvitge), Barcelona, Spain. 28609ass@comb.es

European Journal of Haematology
|May 15, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI.

ESMO open·2025
Same author

Neuroprotective Effects of VGLUT1 Inhibition in HT22 Cells Overexpressing VGLUT1 Under Oxygen Glucose Deprivation Conditions.

Neuromolecular medicine·2024
Same author

Chicago sky blue 6B exerts neuroprotective and anti-inflammatory effects on focal cerebral ischemia.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023
Same author

Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.

Bone marrow transplantation·2023
Same author

Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.

British journal of haematology·2023
Same author

Corrigendum to "Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 31 (2020) 17-29].

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Morphologic subtypes of diffuse large B-cell lymphoma, centroblastic and immunoblastic, show no significant differences in clinical features or treatment response. This suggests the subdivision has limited clinical and prognostic value for diffuse large B-cell lymphoma patients.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • The REAL classification groups diverse morphologic subtypes under diffuse large B-cell lymphoma (DLBCL).
  • Understanding the clinical significance of these subtypes is crucial for patient management.

Purpose of the Study:

  • To evaluate the impact of morphologic subdivision within DLBCL.
  • To determine if centroblastic (CB) and immunoblastic (IB) subtypes influence clinical features and treatment response.

Main Methods:

  • Retrospective analysis of 132 de novo DLBCL patients diagnosed between 1993-1996.
  • Classification using REAL and Updated Kiel classifications with immunohistochemistry.
  • Assessment of clinical features, laboratory parameters, and treatment response.

Related Experiment Videos

Main Results:

  • Of 105 assessable patients, 80 were CB (74%) and 25 were IB (26%).
  • No significant differences were observed between CB and IB groups in clinical features or laboratory parameters.
  • Complete response rates and 2-year survival were similar (49% CB vs. 45% IB).

Conclusions:

  • Morphologic subdivision of DLBCL into CB and IB subtypes offers limited clinical and prognostic significance.
  • Current therapeutic approaches yield similar outcomes for both subtypes.
  • Further research may explore other factors influencing DLBCL prognosis.